Published in Lab Law Weekly, February 2nd, 2007
Picoplatin, the company's lead product candidate, is a new generation platinum therapy with an improved safety profile. It is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Poniard received orphan drug designation in November 2005 from the FDA for picoplatin for the treatment of SCLC.
"This SPA agreement with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly